11.65
-0.09(-0.77%)
Currency In USD
| Previous Close | 11.74 |
| Open | 11.49 |
| Day High | 12 |
| Day Low | 11.25 |
| 52-Week High | 37 |
| 52-Week Low | 8.72 |
| Volume | 153,394 |
| Average Volume | 185,153 |
| Market Cap | 321.04M |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 11.74 |
| Moving Average 200 Days | 14.37 |
| Change | -0.09 |
If you invested $1000 in Crescent Biopharma, Inc. (CBIO) 10 years ago, it would be worth $127,485.25 as of February 21, 2026 at a share price of $11.65. Whereas If you bought $1000 worth of Crescent Biopharma, Inc. (CBIO) shares 5 years ago, it would be worth $44,630.89 as of February 21, 2026 at a share price of $11.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
GlobeNewswire Inc.
Feb 18, 2026 12:30 PM GMT
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients Company anticipates reporting proof-of-concept d
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 12:30 PM GMT
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today ann
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data anticipated in first quarter of 2027 Cre